- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07694492
Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid
Determining the Feasibility of Utilizing a Medical-Legal Partnership Model to Reach Coal Miners Who Use Tobacco and Nicotine Products and Connect Them to a Pharmacy-based Cessation Program
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Background and rationale. Lung cancer rates are approximately 25% higher in Central Appalachia than in the rest of the U.S., and black-lung mortality has been markedly elevated in the region. Coal miners report the highest rates of cigarette smoking (about 23% vs. ~14% nationally) and smokeless tobacco use (about 23% vs. ~3% nationally) of any U.S. occupation, and TNP use magnifies the risk and severity of obstructive lung disease and lung cancer in this already high-risk group. National guidelines recommend that clinicians refer TNP users to cessation services via ask-advise-connect, but time constraints, limited provider buy-in, and patient factors limit adoption. In workers' compensation cases, claimants must prove their disease results from coal-dust exposure rather than TNP use, which creates both a health and a financial incentive for cessation and gives the miner-lawyer relationship unusual salience. This study leverages that relationship by having lawyers ask about TNP use (already routine at intake), advise quitting, and connect interested clients to a pharmacist-delivered cessation program (the novel component). QuitAid, previously developed and piloted by the study team, is a pharmacist-delivered MTM intervention designed to increase NRT adherence and promote cessation.
Aim 1 (implementation evaluation, lawyers). Guided by the Consolidated Framework for Implementation Research (CFIR), the team evaluates facilitators and barriers to adopting the ask-advise-connect model in approximately three black-lung law offices. Lawyers (up to 5 enrolled) complete baseline and follow-up surveys assessing self-efficacy, attitudes, and perceived facilitators/barriers, and participate in ~30-minute semi-structured telephone interviews (audio-recorded, analyzed thematically). Recruitment feasibility is measured by the proportion of coal miners referred per office and the number enrolled per month. Lawyers are study participants only, not investigators, and referral has no effect on a miner's legal case.
Aim 2 (randomized feasibility pilot, coal miners). Coal miners who use TNPs and have a current black-lung workers' compensation case with a participating law office are referred, screened, and consented by phone, complete a baseline assessment, and are then randomized 1:1 via computer-generated permuted-block randomization (generated in R, embedded in REDCap) to QuitAid (Yes vs. No). All participants receive 24 weeks of NRT beginning in Week 1 regardless of readiness to quit. Participants use of smoked TNPs (cigarettes, e-cigarettes, little cigars, cigarillos, cigars) receive the long-acting NRT patch; those using oral TNPs (smokeless tobacco, nicotine pouches) receive short-acting NRT gum; those using both receive the patch. Participants randomized to QuitAid who are ready to quit receive six telephonic pharmacist coaching sessions over 4 weeks; those not ready to quit receive up to three telephonic Pre-Quit Motivation Modules and may transition to QuitAid if they report readiness at any weekly check-in during Weeks 1-4. If readiness is not reported after four weekly check-ins, QuitAid ends. Follow-up assessments are conducted with all participants at 1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks via secure REDCap links or telephone. Because this is a feasibility pilot, secondary clinical outcomes are analyzed descriptively and with logistic regression only to inform a future full-scale trial.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Dylan Allanson, MPH, RD
- Número de telefone: 4342430424
- E-mail: da4ac@virginia.edu
Estude backup de contato
- Nome: Ashley N DeMoss, MPH
- Número de telefone: (304) 574-8073
- E-mail: fzv3nn@virginia.edu
Locais de estudo
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- University of Virginia
-
Subinvestigador:
- Roger T Anderson, PhD
-
Contato:
- Ashley N DeMoss, MPH
- Número de telefone: (304) 574-8073
- E-mail: fzv3nn@virginia.edu
-
Investigador principal:
- Melissa A Little, PhD, MPH
-
Investigador principal:
- Drew Harris, MD
-
Subinvestigador:
- Candace H Wood, PharmD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age ≥ 18 years
- Able to read, speak, and understand English
- A coal miner who uses tobacco and nicotine products, lives in the U.S., and has a current black-lung workers' compensation case with a participating law office
- Reports using tobacco and nicotine products daily for the past 6 months
- Willing and able to use NRT in the form of patch or gum
- Not pregnant or planning to become pregnant in the next 6 months
Exclusion Criteria:
- Medical contraindication to NRT (e.g., within the past 30 days: heart attack or stroke; within the past 6 months: serious or worsening angina, or very rapid or irregular heartbeat requiring medication)
- Pregnant or breastfeeding, or planning to become pregnant during the next 6 months
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: QuitAid + NRT
Participants receive the pharmacist-delivered QuitAid MTM program plus 24 weeks of NRT.
Those ready to quit receive six telephonic coaching sessions over 4 weeks; those not ready to quit receive up to three Pre-Quit Motivation Modules and may transition to QuitAid upon reporting readiness at a weekly check-in (Weeks 1-4).
|
Six telephonic pharmacist coaching sessions over 4 weeks focused on setting a quit date and quitting TNPs.
The first session (and subsequent proactive calls at ~days 2, 7, 14, 21, and 28) addresses negative beliefs about NRT, strengthens motivation and commitment to NRT use, monitors NRT use, provides feedback, and supports adherence.
Includes the Pre-Quit Motivation Modules (up to three telephonic sessions) for participants not yet ready to quit.
Outros nomes:
24 weeks of NRT dispensed under a standing order and mailed to participants, with standard use guidelines.
Product is matched to TNP type: long-acting patch for smoked TNP users, short-acting gum for oral TNP users, patch for dual users.
|
|
Comparador Ativo: NRT Only
Participants receive 24 weeks of NRT beginning in Week 1 without the QuitAid MTM program.
All follow-up assessments are conducted regardless of condition.
|
24 weeks of NRT dispensed under a standing order and mailed to participants, with standard use guidelines.
Product is matched to TNP type: long-acting patch for smoked TNP users, short-acting gum for oral TNP users, patch for dual users.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Feasibility of Randomization
Prazo: Through study recruitment (approximately 6 months)
|
Number of coal miners who need to be approached and screened in order to randomize 100 TNP users.
|
Through study recruitment (approximately 6 months)
|
|
Retention
Prazo: 26 weeks
|
Proportion of randomized coal miners who complete the 26-week follow-up visit.
|
26 weeks
|
|
Fidelity of Implementation
Prazo: Through the 4-week intervention period
|
Fidelity of QuitAid delivery, assessed as adherence to QuitAid, quality of program delivery, participant responsiveness, and program differentiation, captured via a session checklist and self-reported end-of-session reflections.
|
Through the 4-week intervention period
|
|
Dose of the Medication Therapy Management (MTM) Intervention
Prazo: Through the 4-week intervention period
|
Number of MTM (QuitAid) sessions received per participant, documented in the REDCap database.
|
Through the 4-week intervention period
|
|
Dose of NRT
Prazo: Baseline through 26 weeks
|
Reported proportion of provided NRT that was used by participants.
|
Baseline through 26 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Self-Reported Tobacco Abstinence
Prazo: 1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks
|
Self-reported abstinence, defined as no use of any tobacco or nicotine products within the past 7 days.
|
1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks
|
|
Quit Attempts
Prazo: Baseline through 26 weeks
|
Number of quit attempts since the previous contact, where a quit attempt is abstinence for ≥24 hours not due to involuntary or forced cessation (e.g., hospitalization).
|
Baseline through 26 weeks
|
|
Frequency of Urges to Use TNPs
Prazo: Baseline through 26 weeks
|
Self-reported frequency of urges to use tobacco/nicotine products.
|
Baseline through 26 weeks
|
|
Adherence to Assigned Treatment(s)
Prazo: Baseline through 26 weeks
|
Percentage of intervention sessions completed and percentage of provided NRT used.
|
Baseline through 26 weeks
|
|
Adherence to NRT
Prazo: Baseline through 26 weeks
|
Adherence to NRT (patch or gum), measured as the percentage of provided NRT used.
|
Baseline through 26 weeks
|
|
Strength of urges to use TNPs
Prazo: Baseline through 26 weeks
|
Self-reported strength of urges to use tobacco/nicotine products.
|
Baseline through 26 weeks
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Program satisfaction
Prazo: 26 weeks
|
Participant-reported barriers to treatment utilization, satisfaction with treatment components, and suggestions for improvement, with items focused on perceived capacity and opportunity to engage with the interventions.
|
26 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Melissa A Little, PhD, MPH, University of Virginia
- Investigador principal: Drew Harris, MD, University of Virginia
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Transtornos Mentais, Desordem Mental
- Doenças Respiratórias
- Doenças pulmonares
- Transtornos Relacionados a Substâncias
- Distúrbios induzidos quimicamente
- Doenças Pulmonares Intersticiais
- Lesão pulmonar
- Pneumoconiose
- Comportamento
- Comportamento de saúde
- Transtorno do Uso de Tabaco
- Parar de fumar
- Cessação do Tabagismo
- Antracose
- Administração de Serviços de Saúde
- Terapêutica
- Terapia medicamentosa
- Serviços de Saúde
- Instalações de saúde Força e serviços de trabalho
- Economia de saúde e organizações
- Gerenciamento de atendimento ao paciente
- Financiamento, organizado
- Economia
- Serviços Farmacêuticos
- Medicare Parte D
- Seguros, Serviços Farmacêuticos
- Seguro de Saúde
- Seguro
- Medicare
- Terapia de reposição de nicotina
- Gestão da Terapia Medicamentosa
Outros números de identificação do estudo
- HSR 303071
- 5P30CA044579-30 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .